Targeting inhibition of Foxp3 by a CD28 2‿Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy

详细信息    查看全文

• 作者：Teresa Lozano^a ; ^b ; ¹ ; Mario Martí ; nez Soldevilla^b ; ^c ; ¹ ; Noelia Casares^a ; ^b ; ¹ ; Helena Villanueva^b ; ^c ; Maurizio Bendandi^d ; Juan Jose Lasarte^a ; ^b ; ² ; Fernando Pastor^b ; ^c ; ² ; ^{fpasordri@unav.es" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Aptamer ; Therapeutic ; Immunotherapy ; FOXP3 ; Treg
• 刊名：Biomaterials
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：91
• 期：Complete
• 页码：73-80
• 全文大小：891 K

文摘

The specific inhibition of Treg function has long been a major technical challenge in cancer immunotherapy. So far no single cell-surface marker has been identified that could be used to distinguish Treg cells from other lymphocytes. The only available specific marker mostly expressed in Treg is Foxp3, which is an intracellular transcription factor. A targeting molecule able to penetrate the membrane and inhibit Foxp3 within the cell is needed. P60-peptide is able to do that, but due to lack of target specificity, the doses are extremely high. In this study we have shown as a proof of concept that P60 Foxp3 inhibitor peptide can be conjugated with a CD28 targeting aptamer to deliver the peptide to CD28-expressing cells. The AptCD28-P60 construct is a clinically feasible reagent that improves the efficacy of the unconjugated P60 peptide very significantly. This approach was used to inhibit Treg function in a vaccination context, and it has shown a significant improvement in the induced immune response, entailing a lower tumor load in an antigen-specific cancer vaccine protocol.